Cabaletta Bio Inc. (CABA:NASDAQ) released its Q4 2025 and full-year 2025 financial results on March 23, 2026. Cabaletta focuses on late-stage biotechnology and targeted cell therapies for autoimmune diseases and is headquartered in Philadelphia, U.S.
A news release from the company said that Cabaletta closed 2025 with a cash balance of US$133.6 million, which was down from US$164 million in 2024. Since the beginning of 2026, however, the company has raised an additional US$30 million from common stock warrants set to expire in September of this year and ATM sales.
Research and development costs went up as well in Q4 2025 and full-year 2025, from US$25.5 million and US$97.2 million, respectively, in 2024 to US$36.2 million and US$142.7 million in 2025. Administrative expenses stayed relatively level in 2025, though, with Q4 2025 and full-year 2025 costs at US$6.4 million and US$29.6 million, respectively, and 2025 costs coming in at US$8.3 million and US$27.9 million.
Cabaletta is working on a new T cell therapy called rese-cel. It is ". . . an investigational, autologous CAR T cell therapy engineered with a fully human CD19 binder and a 4-1BB co-stimulatory domain, designed specifically for the treatment of autoimmune diseases. Administered as a single, weight-based infusion, rese-cel has demonstrated the ability to transiently, reliably, and deeply deplete CD19-positive cells, with the goal of resetting the immune system and achieving durable clinical responses without the need for chronic therapy. Cabaletta is evaluating rese-cel in the RESET™ (REstoring SElf-Tolerance) clinical development program, which includes multiple ongoing company-sponsored trials across a broad range of autoimmune diseases in rheumatology, neurology, and dermatology."
Wavering Pharma Sector Still Up
Pharma sector funding fell between 2024 and 2025, according to a March 26, 2026, article for Fierce Biotech by Nick Paul Taylor. He wrote that pharma funding had fallen from 2024 but noted that, "2025 was still the third-best year of the past decade. Similarly, overall funding was well above the pre-pandemic norm and only topped by 2020, 2021, and 2024."
At the same time, J. Edward Moreno of Sherwood News reported contradictory news on January 14, 2026, writing that, "In 2025, announced global biotech deals totaled US$228.4 billion, up from US$132.3 billion in 2024, data from Dealogic shows . . . Just two weeks into 2026, US$9.2 billion in deals have been announced."
According to Moreno, movement is expected in the sector: "As some of the most lucrative drugs lose exclusivity in the next few years, pharmaceutical giants are increasingly shopping around for biotechs to add to their portfolios — and they are more than happy to pay a hefty premium for the right company . . . For some Big Pharma companies, business development spending is now about equal to, or more than, research and development."
This statement could explain the emerging drop in research and development spending at biotech and pharma companies. On March 25, 2026, BioSpace's Annalee Armstrong reported that, "R&D spending at the top 16 pharmaceutical companies declined by 3.6% overall in 2025, as many aggressively cut spending and refocused pipelines."
Production Potential Earns 'Buy' Rating
Douglas Tsao and Luci Lai for H.C. Wainwright & Co. gave Cabaletta Bio a 'Buy' rating on April 1, 2026, citing its outpatient dosing trial as an important feature of the rese-cel program.
Commenting on the company's pairing with Cellares' Cell Shuttle system, the analysts wrote, " We believe rese-cel's ease of administration is a competitive differentiator that will matter. If outpatient administration proves feasible in practice, it should reduce hospital resource use and make rese-cel easier to adopt than traditional oncology CAR T." According to the analysts, Cabaletta management has stated that the company has enough capital to fund its current operating plan for the rest of the year.
The analysts closed their report by offering a target price of US$16.
Catalysts
"As we advance our core clinical programs for rese-cel with preconditioning and standard manufacturing, we have meaningfully advanced two potentially transformative innovations: rese-cel with no preconditioning and automated manufacturing using the Cellares Cell Shuttle. Clinical data on both innovations are on track to be shared in the first half of this year with durability data to follow later this year. Clinical data currently suggest that rese-cel offers a competitive profile that may reliably deliver an immune reset following a single, weight-based infusion with a safety profile that facilitates outpatient delivery with — or potentially without — preconditioning," said Steven Nichtberger, M.D., and CEO of Cabaletta, on March 23, 2026.
In the first half of 2026, Cabaletta expects to report the initial clinical experience with rese-cel through Cellares' manufacturing platform. The company's goal is to ensure Good Manufacturing Practice (GMP) readiness. If the Cellares Integrated Development and Manufacturing (IDMO) Smart Factory trial is successful, Cabaletta will be able to significantly scale production at a minimal cost.
In the second half of 2026, the company hopes to release clinical data from patient trials.
Streetwise Ownership Overview*Two formulas currently being tested, RESET-SLE and RESET-PV, are expected to produce initial data in the first half of 2026 and durable data in the second half. Dose-ranging durability data from RESET-PV trials are expected throughout the year.
The press release also noted that, ". . . The registrational dermatomyositis (DM) and antisynthetase syndrome (ASyS) cohort is enrolling and is expected to evaluate 17 patients with a 16-week primary endpoint of moderate or major total improvement score response while off immunomodulators and on no or low-dose steroids. If successful, data from this cohort will support Cabaletta's first projected Biologics License Application (BLA) submission for rese-cel in myositis in 2027."
Ownership & Share Structure1
Cabaletta Bio Inc. has a market cap of US$299.46 million, with 111.32 million shares outstanding.
The company has a 52-week range of US$0.99-US$3.78.
Institutions hold 68.51% of shares, while Management & Insiders hold 1.46%.
The remaining 30.03% of shares are Retail.
| Want to be the first to know about interesting Biotechnology / Pharmaceuticals investment ideas? Sign up to receive the FREE Streetwise Reports' newsletter. | Subscribe |
Important Disclosures:
- Cori Fisher wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
- This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
- This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.
For additional disclosures, please click here.
1. Ownership and Share Structure Information
The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.
